ENCORE SEOUL

  • Home
  • Contact us
회원로그인 ID PW Forgot ID/PW Register Automatically Log me on

New antiplatelet drugs and novel oral anticoagulant during percutaneous coronary intervention

▶ NOA have significantly improved the outcomes of patients with NVAfib, but have no current role in ACS patients.
▶ NOA are likely to present a better safety profile than VKA in patiens undergoing stent implantation, and RCTs are currently addressing this hypothesis.

▶ Prasugrel and ticagrelor are the standard of care for high risk ACS patients with no increased risk of bleeding.
▶ Cangrelor could be a useful treatment for reducing intraprocedural complication pending approval and drug cost.

DETAIL VIEW
Best Focus

coronary

  • lecture
  • case
read more

vascular

  • lecture
  • case
read more